The family office has offices in Belgium and Luxembourg. The firm makes equity investments in life science companies, typically at the Series A stage or later; the firm allocates a total of EUR 3-15 million over the life of an investment. The majority of the firm’s investments are in Europe (~75%) and the rest are in the US.

In the life science sector, the firm invests in medical applications (therapeutics, diagnostics, and medical devices), digital health, life science services and tools, and agtech / food tech. For therapeutics companies, the firm only invests in companies with assets that have obtained data from in-human clinical trials (at minimum, human safety data is required). For medtech or diagnostic companies, the product must be no more than 1 year from commercialization. For digital health companies, the firm prefers to see companies that have market traction, with 2-3M EUR in revenue. In life science tools, the firm is particularly interested in companies with technologies in the -omics space, drug design platforms, or relating to data. The firm invests broadly in the life science field, but has a specific interest in technologies at the intersection between the healthcare and food industries, including nutraceuticals and the microbiome.

The firm is a hands-on investor that prefers to take a board seat and work closely with management. The firm prefers to invest as part of a strong syndicate that includes experienced investors with whom the firm has pre-existing connections.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

By Caitlin Dolegowski, Marketing Specialist, LSN

Digital RESI JPM, January 11-13 is Life Science Nation (LSN)’s first partnering event of 2022 and features a lineup of must-see panels. These panels are organized with consideration of fundraising, life science entrepreneurs and insights they can learn from expert panelists, featuring unique conversations on how to build relationships and manage expectations in the early-stage fundraising arena. Those attending Digital RESI JPM will have access to the live panels and, additionally, each panel will be recorded and a link to the recordings will be available on our platform for conference attendees to access at their convenience.

Panels at Digital RESI JPM:

Bodil (Bo) Arlander Lead Venture Partner, Portfolia Active Aging & Longevity Fund Portfolia	Joshua Barney Member Barrington Angels	Mel Barsky Director, BD CABHI
Yael Benvenisti CEO Mediterranean Tower Ventures	Jean Anne Booth Founder & CEO UnaliWear Inc.	David Bravo CEO Pannex Therapeutics
Christine Brocato System VP, Strategic Innovation CommonSpirit Health	Patrick Burgermeister Partner KIZOO Technology Ventures	Anke Cassing Investment Manager High-Tech Gründerfonds
Tracy Chadwell Founding Partner 1843 Capital LLC	Sam Cooper CEO Phenomic AI	Marina Cortes Venture Partner Hike Ventures LLC
Leslie Cousens Senior Director, Search & Evaluation Respiratory & Immunology AstraZeneca	Ruchi Dana Board Member Dana Group	Jun Deng Investment Partner Joyance Partners
Dominic Endicott Founding Partner 4Gen Ventures	Erin Denny Director in Business Development Amgen	Stacy Feld Senior Director, Consumer Scientific Innovation Johnson & Johnson Innovation
David Gordon Head of Investments Longliv Ventures	Richard Hanbury CEO Sana Health	Dan Hermann Managing Partner Ziegler LinkAge
Gerard Honig Director, Research Innovation Crohn’s and Colitis Foundation	Jochen Hurlebaus Head of Digital Health Innovation Roche Diagnostics	Shrenik Jain Founder & CEO Marigold Health
Rick Jones Partner BioAdvance	Ekkehard Kauffmann Global BD, M&A Roche Diagnostics	Masashi Kiyomine Partner Kicker Ventures
Stephany Lapierre Founder & CEO TealBook	Keagan Lenihan Vice President, Operations Altoida Inc	Abby Levy Managing Partner Primetime Partners
Tim Luker Senior Director, Emerging Technology & Innovation, Corporate BD Eli Lilly & Co	Fiona MacLaughlin Director Johnson & Johnson Innovation (JLABS)	Henry Mahncke CEO Posit Science
Brian Malkin Partner McDermott Will & Emery	Mark McDade Partner, Boston Qiming Venture Partners	Tom Miller Managing Partner GreyBird Ventures
Brad Murray Senior Associate Xontogeny	Heather Petty Senior Manager, Program Development Xontogeny	Rohit Pratap Singh Vice President, Investments Xeraya Capital
Marc Rippen CEO Alertgy	Roberto Rosas Director Health Innovation Capital	Kerry Rupp General Partner True Wealth Ventures
Beth Sanders Founder & CEO LifeBio	Mark Scher CEO Spiro100	Peter Schlecht CEO & Founder Braingrade
Anu Shukla Co-Founder & Executive Chair Botco.ai	Dor Skuler Co-Founder Intuition Robotics	Yaniv Sneor Founding Member Mid Atlantic Bio Angels
Michelle Snyder Investment Partner McKesson Ventures	John Steuart Managing Director Steuart Ventures	Frances Taheri Global Ventures Digital Health Lead Accenture Ventures
Lauren Tyra Analyst Green Park & Golf Ventures	David Uffer Senior Partner Alira Health Ventures	Hope Walls Investment Analyst Nationwide Ventures
Tad Weems Managing Director Agilent Technologies	Sam Yang Managing Director and Co-Founder Xandar Kardian	Renee Yao Global Healthcare AI Startups BD Lead NVIDIA Corporation
Max Zamkow Partner Third Act Ventures	Lu Zhang Managing Partner Fusion Fund	Mishael Zohar Associate OrbiMed Advisors LLC

By Candice He, Vice President of Business Development, Global Investment Strategist, LSN

Startups can save precious time and resources by seeking investments at Redefining Early Stage Investments (RESI), but service providers like Contract Research Organizations (CROs) are also there to help them achieve their goals better, faster, and cheaper. Designed to simplify entry into drug markets and reduce product development cost for life science companies, CROs support the biotechnology and medical device industries in the form of research services outsourced on a contract basis. Preexisting relationships with CROs and other RESI service providers help startups hit the ground running with their new capital. There are now more than 1,000 CROs, with some serving the global market, and many using RESI to promote their model and services.

Examples:

• Wuxi Apptech (Former RESI Title Sponsor)
• Viva Biotech (Former RESI Gold Sponsor)
• Avance Clinical (Former Exhibitor on RESI Service Provider Showcase)

In addition to the R&D outsourcing model, some CRO companies also have their own incubator or corporate venture capital funds, to support early-stage clients with equity investments or “Service for Equity”, which is designed to be a win-win model. Many fundraising executives are surprised to learn such options exist; some have never even considered an overseas CRO partner. With their biggest expenditure being covered, they can then focus on finding co-investors for a smaller round.

If you want to showcase your CRO brand to more startups in Therapeutics, MedTech and Diagnostics, you should not miss out Digital RESI in 2022. Check out the sponsorship brochure as below for the RESI 2022 schedule and sponsorship options.

Want to learn more? The Business Development team at Life Science Nation is available to answer questions and share additional details to help you meet your partnership goals!
International	East Coast (USA) & China	Midwest (USA) & Canada	West Coast  (USA)
Greg Mannix Vice President International Business Development Book a Meeting Email Me	Candice He VP, Business Development & Global Investment Strategist Book a Meeting Email Me	Antoinette Lowre Manager of Business Development Book a Meeting Email Me	Alexander Vassallo Manager of Business Development Book a Meeting Email Me

By Gregory Mannix, Vice President International Business Development, General Manager Europe, LSN

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

Partnering launches for Digital RESI JPM next week and we are expecting 400-500 investors, including family offices/private wealth, corporate venture capital, large pharma and strategic groups, and more. A diverse assembly of investors participate at every RESI event with a main objective of sourcing early-stage innovations for potential investment, in-licensing, and other partnering strategies. Check out the investors who are currently confirmed to attend:

Confirmed Digital RESI JPM Investors*

Don’t miss the last opportunity to save on registration! Early bird rates end tomorrow, so sign up now to save $200! if you are actively fundraising and seeking to engage with investors that could potentially be interested in your technology, do not miss out on this opportunity and secure the best registration price available!

By Karen Deyo, Director of Investor Research, Israel BD, LSN

Through the years, we at Life Science Nation (LSN) have spoken to startups, investors, service providers and many of the other players in the early-stage life science ecosystem. We have seen what works and what does not, and have put together a series of workshops and bootcamps to pass along this knowledge to emerging startups, to help smooth their journeys and, hopefully, prevent them from making a few common mistakes along the way.

Over the course of the next few weeks, leading up to Digital RESI JPM, January 11-13, LSN staff will be holding a series of free bootcamps for startups. Fundraising executives are welcome to attend as many as they desire! We will cover topics such as (but not limited to): identifying investors who are a fit for you, building a comprehensive marketing collateral package that tells your story, how to optimize your partnering experience at a conference, and how to approach your investor meetings in a way that will increase your chances of a second meeting. Follow the links below to register!

Don’t forget to register for Digital RESI JPM – partnering launches next Monday, December 20, so make sure you are signed up to start booking meetings!